Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia

Blood Adv. 2023 Oct 10;7(19):5877-5889. doi: 10.1182/bloodadvances.2022008207.

Abstract

The importance of the stromal microenvironment in chronic lymphocytic leukemia (CLL) pathogenesis and drug resistance is well established. Despite recent advances in CLL therapy, identifying novel ways to disrupt interactions between CLL and its microenvironment may identify new combination partners for the drugs currently in use. To understand the role of microenvironmental factors on primary CLL cells, we took advantage of an observation that conditioned media (CM) collected from stroma was protective of CLL cells from spontaneous cell death ex vivo. The cytokine in the CM-dependent cells that most supports CLL survival in short-term ex vivo culture was CCL2. Pretreatment of CLL cells with anti-CCL2 antibody enhanced venetoclax-mediated killing. Surprisingly, we found a group of CLL samples (9/23 cases) that are less likely to undergo cell death in the absence of CM support. Functional studies revealed that CM-independent (CMI) CLL cells are less sensitive to apoptosis than conventional stroma-dependent CLL. In addition, a majority of the CMI CLL samples (80%) harbored unmutated immunoglobulin heavy-chain variable (IGHV) region. Bulk-RNA sequence analysis revealed upregulation of the focal adhesion and RAS signaling pathways in this group, along with expression of fms-like tyrosine kinase 3 (FLT3) and CD135. Treatment with FLT3 inhibitors caused a significant reduction in cell viability among CMI samples. In summary, we were able to discriminate and target 2 biologically distinct subgroups of CLL based on CM dependence with distinct microenvironmental vulnerabilities.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Culture Media, Conditioned / pharmacology
  • Humans
  • Immunoglobulin Variable Region / genetics
  • Immunoglobulin Variable Region / therapeutic use
  • Leukemia, Lymphocytic, Chronic, B-Cell* / pathology
  • Signal Transduction
  • Tumor Microenvironment
  • fms-Like Tyrosine Kinase 3 / therapeutic use

Substances

  • Culture Media, Conditioned
  • fms-Like Tyrosine Kinase 3
  • Immunoglobulin Variable Region